{"id":4285,"date":"2020-01-22T22:36:05","date_gmt":"2020-01-23T03:36:05","guid":{"rendered":"https:\/\/thehopenet.org\/blog2\/?p=4285"},"modified":"2020-01-22T22:36:08","modified_gmt":"2020-01-23T03:36:08","slug":"sagetherapeutics","status":"publish","type":"post","link":"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/","title":{"rendered":"New therapy enters Phase II testing"},"content":{"rendered":"\n<p>Sage Therapeutics is about to begin Phase II testing of Sage-324 for Essential Tremor.  There is a lot to learn about the way Sage is thinking about Neurological Disorders on their corporate website at:<\/p>\n\n\n\n<ul><li><a href=\"https:\/\/www.sagerx.com\/programs-research\/neurologic-disorders\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sagerx.com\/programs-research\/neurologic-disorders\/<\/a><\/li><li><a href=\"https:\/\/www.sagerx.com\/programs-research\/pipeline\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sagerx.com\/programs-research\/pipeline\/<\/a><\/li><li><a href=\"https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-clinical-updates-and-progress-across\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"broken_link\">https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-clinical-updates-and-progress-across<\/a><\/li><\/ul>\n\n\n\n<p> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sage Therapeutics is about to begin Phase II testing of Sage-324 for Essential Tremor. There is a lot to learn about the way Sage is thinking about Neurological Disorders on their corporate website at: https:\/\/www.sagerx.com\/programs-research\/neurologic-disorders\/ https:\/\/www.sagerx.com\/programs-research\/pipeline\/ https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-clinical-updates-and-progress-across<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[8,16,19,27,30,1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v16.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New therapy enters Phase II testing - HopeNet<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New therapy enters Phase II testing - HopeNet\" \/>\n<meta property=\"og:description\" content=\"Sage Therapeutics is about to begin Phase II testing of Sage-324 for Essential Tremor. There is a lot to learn about the way Sage is thinking about Neurological Disorders on their corporate website at: https:\/\/www.sagerx.com\/programs-research\/neurologic-disorders\/ https:\/\/www.sagerx.com\/programs-research\/pipeline\/ https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-clinical-updates-and-progress-across\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"HopeNet\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TheHopeNet\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-23T03:36:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-01-23T03:36:08+00:00\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/#website\",\"url\":\"https:\/\/thehopenet.org\/blog2\/\",\"name\":\"HopeNet\",\"description\":\"A guiding light for those affected by Essential Tremor\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/thehopenet.org\/blog2\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/#webpage\",\"url\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\",\"name\":\"New therapy enters Phase II testing - HopeNet\",\"isPartOf\":{\"@id\":\"https:\/\/thehopenet.org\/blog2\/#website\"},\"datePublished\":\"2020-01-23T03:36:05+00:00\",\"dateModified\":\"2020-01-23T03:36:08+00:00\",\"author\":{\"@id\":\"https:\/\/thehopenet.org\/blog2\/#\/schema\/person\/8338336e37ab4f2c544dfd585aaf7a6d\"},\"breadcrumb\":{\"@id\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/\",\"url\":\"https:\/\/thehopenet.org\/blog2\/\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\",\"url\":\"https:\/\/thehopenet.org\/blog2\/sagetherapeutics\/\",\"name\":\"New therapy enters Phase II testing\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/thehopenet.org\/blog2\/#\/schema\/person\/8338336e37ab4f2c544dfd585aaf7a6d\",\"name\":\"HopeNetAdmin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/posts\/4285"}],"collection":[{"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/comments?post=4285"}],"version-history":[{"count":2,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/posts\/4285\/revisions"}],"predecessor-version":[{"id":4289,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/posts\/4285\/revisions\/4289"}],"wp:attachment":[{"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/media?parent=4285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/categories?post=4285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thehopenet.org\/blog2\/wp-json\/wp\/v2\/tags?post=4285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}